Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: Real-world evidence from healthcare workers in Japan

As the first authorized COVID-19 vaccine in Japan, the BNT162b2 mRNA COVID-19 vaccine is utilized for mass vaccination. Although efficacy has been proved, real-world evidence on reactogenicity in Japanese personnel is needed to prepare the public. Healthcare workers in a large academic hospital in J...

Descripción completa

Detalles Bibliográficos
Autores principales: Saita, Mizue, Yan, Yan, Ito, Kanami, Sasano, Hiroshi, Seyama, Kuniaki, Naito, Toshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443338/
https://www.ncbi.nlm.nih.gov/pubmed/34580011
http://dx.doi.org/10.1016/j.jiac.2021.09.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443338/
https://www.ncbi.nlm.nih.gov/pubmed/34580011
http://dx.doi.org/10.1016/j.jiac.2021.09.009

Ejemplares similares